New CAR-T therapy aims to outsmart resistant blood cancers
NCT ID NCT07539610
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new type of immune cell therapy called Sup19 CAR-T in 9 adults with B-cell acute lymphoblastic leukemia or lymphoma. It is for patients whose cancer stopped responding to previous CD19-targeted treatments or has low levels of CD19. The main goal is to check safety and see if the therapy can help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sup19 CAR-T cells (a type of immune cell therapy)
- What this could lead to
- If it works, this could offer a new treatment option for people with certain blood cancers who have run out of other CD19-targeted therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 9 participants, so it is too small to prove effectiveness. There are also known risks like severe immune reactions (CRS and ICANS).
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology, Chinese Academy of Medical Sciences & Hospital of Hematology, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chemo-Antibody combo beat a tough leukemia?
- Could a simple drug tame the dangerous side effects of CAR-T cancer therapy?
- Engineered immune cells take aim at tough childhood leukemia
- New combo aims to wipe out hidden leukemia cells
- Could a One-Time immune cell infusion help older leukemia patients avoid harsh chemo?
- New combo therapy aims to outsmart leukemia in older patients